The “U.S. Women Health Laboratory Testing Market – A Region-Wise Analysis: Focus on U.S. Women Health Laboratory Testing Market – Analysis and Forecast, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The U.S. women health laboratory testing market was valued at $72.8 billion in 2021 and is anticipated to reach $106.8 billion by 2030, witnessing a CAGR of 4.30% during the forecast period 2022-2030.
The market is driven by factors such as the increase in the prevalence of infectious diseases and cancer in women, rising awareness regarding women health-related tests, the rising average maternal age leading to increased risk of fetal chromosomal aneuploidies, and the upsurge in reproductive health problems leading to increased demand for laboratory testing in women.
The U.S. women health laboratory testing market is in the developed phase. The advancements in diagnostic technologies including applications of genetic testing in women’s health and the significant number of mergers and acquisitions of companies to attain a better market share are some of the major opportunities in the U.S. women health laboratory testing market.
How can this report add value to an organization?
The different segment of the report helps the reader understand the different type of laboratory tests/services for women’s health available in the market.
Moreover, the study provides the reader with a detailed understanding of tests/services that fall under the different segments, which are hereditary cancer, carrier screening, prenatal screening, and diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology.
Growth/Marketing Strategy: The U.S. women health laboratory testing market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, merger and acquisitions, funding activities, and regulatory and legal approvals.
The favored strategy for the companies has been regulatory and legal activities to strengthen the position of their product in the U.S. market. For instance, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in Late-line Ovarian Cancer.
Recent Developments in the U.S. Women Health Laboratory Testing Market
Key Topics Covered:
1.1 U.S. Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Business Dynamics
1.2.1 Impact Analysis
1.2.2 Business Drivers
126.96.36.199 Increase in the Prevalence of Infectious Diseases and Cancer in Women Leading to Increased Demand for Laboratory Diagnostics
188.8.131.52 Rising Awareness Regarding Women Health-Related Tests
184.108.40.206 Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies
220.127.116.11 Upsurge in Reproductive Health Problems Leading to Increased Demand for Laboratory Testing in Women
1.2.3 Business Restraints
18.104.22.168 Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.
22.214.171.124 Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.
1.2.4 Business Opportunities
126.96.36.199 Advancement in Diagnostic Technologies, including Applications of Genetic Testing in Women’s Health
188.8.131.52 Healthcare Disparities in the Rural Counties of the U.S.
184.108.40.206 Gap in Healthcare for Women of Reproductive Age with Psychological Distress
220.127.116.11 Significant Number of Mergers and Acquisitions by Companies to Attain a Better Market Share
2 U.S. Women Health Laboratory Testing Market (by Hereditary Cancer)
2.2 Breast Cancer
2.2.2 Testing Market
2.2.3 Testing Market (by Region)
2.3 Cervical Cancer
2.4 Ovarian Cancer
3 U.S. Women Health Laboratory Testing Market (by Carrier Screening)
3.1.1 Testing Market
3.1.2 Testing Market (by Region)
4 U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)
4.2 Non-Invasive Prenatal Testing (NIPT)
4.3 Maternal Serum Screening (MSS)
4.4 Prenatal Diagnostic Testing
5 U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)
5.2 Pregnancy and Ovulation Testing
5.3 HPV Testing
5.4 PAP Smear Testing
5.5 HIV Testing
5.6 CT/NG Testing
5.7 Preimplantation Genetic Testing (PGT)
5.8 Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia)
5.9 Herpes Simplex Virus (HSV)
5.11 Vaginal Infections
6 U.S. Women Health Laboratory Testing Market (by Obstetrics and Gynaecology)
6.1.1 Testing Market (by Region)
For more information about this report visit https://www.researchandmarkets.com/r/eetogi-s-women-health?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716